Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office
One year after the spread of the pandemic, we analyzed the assessment results of the quality documentation submitted to the Clinical Trials Office of the Italian Medicines Agency as part of the request for authorization of clinical trials with a COVID-19 indication. In this article, we report the cl...
Saved in:
Main Authors: | Diego Alejandro Dri (Author), Giulia Praticò (Author), Elisa Gaucci (Author), Carlotta Marianecci (Author), Donatella Gramaglia (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office
by: Diego Alejandro Dri, et al.
Published: (2022) -
Surfactants, Nanomedicines and Nanocarriers: A Critical Evaluation on Clinical Trials
by: Diego Alejandro Dri, et al.
Published: (2021) -
Study design of herbal medicine clinical trials: a descriptive analysis of published studies investigating the effects of herbal medicinal products on human participants
by: Nut Koonrungsesomboon, et al.
Published: (2024) -
Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial
by: Sadahiro Naka, et al.
Published: (2024) -
Plant Medicines for Clinical Trial
by: James David Adams (Ed.)
Published: (2018)